Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1252W HIGH $3.96
Volume
93.91 K
Value Traded
182.86 K
Short % Float
2.26%
+3.9%Week
-30.13%1 Month
-28.25%3 Month
+26.98%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
83.20 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
52.70 M
Total Shares
52.00 M
Float Shares
35.05 M
Insiders
32.60%
Institutions
7.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RFL Catalyst Timeline
Dated clinical, regulatory and corporate events for Rafael Holdings, Inc. Class B Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rafael Holdings, Inc. Class B Common Stock
156Total events
4Upcoming
43Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Subgroup AnalysisClinical Data
Prespecified analysis showed statistically significant treatment effect on 4DNPCSS in patients on background miglustat and/or leucine
Niemann-Pick Disease Type C (NPC)source ↗
▲Safety Data UpdateClinical Data
Trappsol Cyclo demonstrated well-tolerated safety profile with no new safety signals over 96 weeks
Niemann-Pick Disease Type C (NPC)source ↗
▼Primary Endpoint MissedClinical Data
Primary endpoint of change in 4DNPCSS at Week 96 did not achieve statistical significance
Niemann-Pick Disease Type C (NPC)source ↗
◆Topline ReadoutClinical Data
Topline results from pivotal Phase 3 TransportNPC study of Trappsol Cyclo in NPC
Niemann-Pick Disease Type C (NPC)source ↗
▲Additional DataClinical Data
Separate overall survival analysis showed treatment-associated survival benefit vs INPDR and expanded historical controls
infantile-onset Niemann-Pick Disease Type C (NPC)source ↗
◆Topline ReadoutClinical Data
Preliminary top line results expected in Q3 2026
Niemann-Pick Disease Type C1source ↗
▲Last Patient Last VisitTrial
Last patient completed final 96-week study visit in pivotal Phase 3 TransportNPC study
Niemann-Pick Disease Type Csource ↗
▲IND ClearanceIND
FDA acknowledgement that US Expanded Access Program can proceed
Niemann-Pick Disease Type Csource ↗
▲Partnership / LicenseCorporate
Exclusive licensing agreement with MIT for patent covering cyclodextrins in ApoE4-positive Alzheimer's Disease
Alzheimer's Disease (ApoE4 positive)source ↗
◆Topline ReadoutClinical Data
Topline data from main study cohort expected to be announced
Niemann-Pick Disease Type Csource ↗
▲DSMB ReviewTrial
DMC recommended continuation after review of 48-week safety and efficacy data
Niemann-Pick Disease Type C1source ↗
▲Oral PresentationPresentation
Data presented at WORLDSymposium 2026 from single arm pediatric sub-study
Niemann-Pick Disease Type Csource ↗
▲DSMB ReviewTrial
DMC recommended continuing after review of prespecified safety and efficacy data at 48 weeks
Niemann-Pick Disease Type C1source ↗
▲DSMB ReviewTrial
DMC recommended continuation of TransportNPC Phase 3 trial after review of 48-week safety and efficacy data
Niemann-Pick Disease Type C1source ↗
●Management ChangeCorporate
Markus Sieger elected Lead Independent Director and Audit Committee Chair
◆AcquisitionCorporate
Planned merger with Cyclo Therapeutics anticipated to close in Q3 pending shareholder approvals
▲DSMB ReviewTrial
DMC review of prespecified 48-week interim data recommends continuation of Phase 3 TransportNPC study
Niemann-Pick Disease Type C1 (NPC1)source ↗
▲Timing GuidancePresentation
FDA accepted statistical analysis plan for TransportNPC study
Niemann-Pick Disease Type C1 (NPC1)source ↗
▲Interim AnalysisTrial
48-week interim analysis completed; DMC recommended continuation to final analysis
Niemann-Pick Disease Type Csource ↗
▲Enrollment CompleteTrial
TransportNPC Phase 3 trial fully enrolled
Niemann-Pick Disease Type C1source ↗
◆Interim AnalysisTrial
48-week interim analysis results expected later this month
Niemann-Pick Disease Type C1source ↗
▼Equity OfferingCorporate
Rights offering of $25 million to support development of Trappsol Cyclo
▼Equity OfferingCorporate
Rights offering of $25 million to support potential launch of Trappsol Cyclo
▲Enrollment CompleteTrial
TransportNPC Phase 3 trial fully enrolled
Niemann-Pick Disease Type C1source ↗
◆Topline ReadoutClinical Data
Topline data from 48-week interim analysis of 104 enrolled patients expected
Niemann-Pick Disease Type C1source ↗
▲Enrollment CompleteTrial
TransportNPC Phase 3 trial fully enrolled
Niemann-Pick Disease Type C1source ↗
◆Oral PresentationPresentation
Preliminary results presented at 21st Annual WORLDSymposium
Niemann-Pick Disease Type C1source ↗
◆AcquisitionCorporate
Rafael Holdings and Cyclo Therapeutics enter into definitive merger agreement
Past FDA Catalysts and PDUFA Decisions
How RFL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-06-30 | CPI-613® (devimistat) | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RFL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Trappsol® Cyclo™ Fast TrackOrphanRare Pediatric | Niemann-Pick Disease Type C | Phase 3 | 2026-09-30 | primary endpoint: LS mean change Trappsol Cyclo 0.46, Placebo 1.28, difference -0.81, p value 0.19, statistical significance false; prespecified analysis: LS mean change Trappsol Cyclo 0.46, Placebo 1.57, difference -1.11, p value 0.046, statistical significance true; safety profile: TEAEs Trappsol Cyclo 93.8%, Placebo 100.0%, serious TEAEs Trappsol Cyclo 35.9%, Placebo 16.7%, treatment related serious TEAEs Trappsol Cyclo 3.1%, Placebo 3.3%, hearing related TEAEs Trappsol Cyclo 15.6%, Placebo 13.3%Read More | Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Polinsky DavidOfficer (Chief Financial Officer) | Disposition | -2,318 301,497 held | $1.28 | 03/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RFL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 0.1 % (-66.7 %) | 304.00 K | 121.00 K | -57.65% ( -164.71 K) |
RFL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RFL ranks across every disease it competes in
Competitive Position is a premium feature
See how RFL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRFL News
-RFL
Sep 30, 2026▼ -35%on this news
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
Rafael Holdings announced topline results from the Phase 3 TransportNPC™ study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C. While the primary endpoint did not achieve statistical significance, a prespecified analysis showed a significant treatment effect in patients receiving background therapy. The drug demonstrated a well-tolerated safety profile, and the company plans to submit an NDA in Q4 2026.
Read more →-RFL
Sep 1, 2026▼ -5.1%on this news
Dr. Akash Sharma and Dr. Rafael Tua-Caraccia Join Greater Boston Urology, an Affiliate of U.S. Urology Partners
Greater Boston Urology has announced the addition of Dr. Akash Sharma and Dr. Rafael Tua-Caraccia to its team. This expansion aims to enhance access to urology and urogynecology services in the region. The move reflects a commitment to improving patient care through the recruitment of skilled professionals.
Read more →-RFL
Aug 26, 2026Sofis Announces Appointment of Rafael Fraga as CEO
Sofis has appointed Rafael Fraga as its new CEO, succeeding founder Reynaldo Mendes, who will remain involved in the company. This leadership change follows Arcadea Group's acquisition of a majority stake in Sofis earlier in 2026. Fraga brings significant experience in the software industry, which is anticipated to enhance the company's growth.
Read more →-RFL
Jul 9, 2026▼ -7.3%on this news
Ronald McDonald House Westside LA Receives $1 Million Gift From The Rafael and Sharyl Mendez Family Foundation
Ronald McDonald House Westside LA has received a generous $1 million donation from The Rafael and Sharyl Mendez Family Foundation. This funding will aid in establishing a new Ronald McDonald House on Hilgard Avenue in Westwood Village. The facility aims to provide essential support for families with hospitalized children, helping them stay close during difficult times.
Read more →-RFL
Jun 11, 2026▲ +19.1%on this news· ran to +43% by day 3
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings reported its financial results for Q3 FY 2026, highlighting the completion of its pivotal Phase 3 TransportNPC trial. The company anticipates submitting its New Drug Application in the latter half of 2026, aiming to address the unmet needs of Niemann-Pick Disease Type C1. Despite a net loss of $4.2 million, the company sees potential for long-term shareholder value.
Read more →-RFL
Jun 10, 2026▼ -7.8%on this newsshared move
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Rafael Holdings has completed the last patient visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C. The study involved 94 patients across 27 sites globally. Topline results are expected in the second half of 2026, with the company planning to submit an NDA following a pre-NDA meeting with the FDA.
Read more →-RFL
Apr 22, 2026Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"
Rafael Holdings, Inc. has secured an exclusive licensing agreement with MIT for a patent related to cyclodextrins aimed at improving myelination in ApoE4 positive Alzheimer's disease patients. This licensing strengthens Rafael's intellectual property portfolio regarding its lead candidate, Trappsol Cyclo, which could significantly impact the treatment landscape for a substantial patient population. Preclinical data suggests that Trappsol Cyclo may enhance cholesterol delivery within the central nervous system and improve cognitive functions. The agreement marks a pivotal step for Rafael Holdings in its clinical development efforts.
Read more →-RFL
Mar 16, 2026Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
Rafael Holdings, Inc. has reported its financial results for the second quarter of fiscal 2026, which showed an increased net loss largely attributed to the consolidation of Cyclo Therapeutics' expenses post-acquisition. Despite the financial challenges, the company is optimistic about its pivotal Phase 3 study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1, with positive recommendations from the Data Monitoring Committee. The company anticipates providing preliminary results in the upcoming third quarter, aiming to advance treatment options for this rare genetic disorder.
Read more →-RFL
Dec 11, 2025Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
Rafael Holdings, Inc. reported its financial results for the first quarter of fiscal year 2026, ending October 31, showing a net loss of $9.8 million. Despite the increased losses largely due to consolidation costs from the acquisition of Cyclo Therapeutics, the company expressed satisfaction with the progress of their Phase 3 TransportNPC study for Trappsol Cyclo. The Data Monitoring Committee has advised continuing the study based on positive safety and efficacy reviews, offering hope for patients with Niemann-Pick Disease Type C1.
Read more →-RFL
Oct 29, 2025Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Rafael Holdings has reported its financial results for the fourth quarter and full fiscal year 2025. The company highlighted ongoing progress in its pivotal Phase 3 clinical trial for Trappsol Cyclo, aimed at treating Niemann-Pick Disease Type C1. Despite achieving a successful rights offering, Rafael Holdings faced an increase in net loss due to consolidated expenses following recent acquisitions. Total cash and cash equivalents reported as of July 31, 2025, were $52.8 million.
Read more →-RFL
Oct 28, 2025Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
Rafael Holdings announced the passing of Lead Independent Director Stephen Greenberg and appointed Alan Grayson to its Board of Directors. Grayson will contribute his extensive legal and government experience, while existing board member Markus Sieger will serve as the new Lead Independent Director. The company acknowledges Greenberg's contributions, marking a significant change in its leadership structure. This governance transition might impact stakeholders as the company continues its strategic directions.
Read more →-RFL
Oct 10, 2025NASDAQ: RFL October 2025 | Investor Presentation Forward - Looking Statements Some of the information in this presentation relates to future events or future business and financial performance . Such statements constitut
Rafael Holdings, Inc. has provided an investor presentation detailing forward-looking statements primarily surrounding its lead product, Trappsol Cyclo, which is currently in Phase 3 trials for treating Niemann-Pick Disease Type C. The presentation outlines significant investment highlights, including a strong market potential, upcoming regulatory submissions, and positive interim analysis recommendations. Nevertheless, the company faces substantial risks, including dependency on the drug's regulatory approval and potential challenges in clinical trial outcomes. Overall, Rafael Holdings aims to deliver innovative therapies for patients with unmet medical needs.
Read more →-RFL
Sep 16, 2025▲ +6.8%on this news
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
Rafael Holdings presented preliminary data from its Phase 3 TransportNPC study at the ICIEM. The data indicates that seven out of nine patients under three years old showed stabilization or improvement in their condition after 48 weeks of treatment with Trappsol Cyclo. The study aims to evaluate the safety and efficacy of this investigational drug for Niemann-Pick Disease Type C1.
Read more →-RFL
Aug 27, 2025Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
Rafael Holdings announced that its subsidiary Cyclo Therapeutics will present two abstracts at the 15th International Congress of Inborn Errors of Metabolism in Kyoto, Japan. The presentations will focus on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, highlighting efficacy and safety data from clinical studies. This marks a significant step in the ongoing research and development of treatments for this rare genetic disorder.
Read more →-RFL
Jul 14, 2025▲ +6.3%on this news
FOURTH AMENDED AND RESTATED BY-LAWS OF RAFAEL HOLDINGS, INC. (hereinafter called the "Corporation") Effective as of
Rafael Holdings, Inc. has made amendments to its by-laws, effective July 14, 2025. The revisions include details regarding the corporation's registered office location, meeting protocols for stockholders, quorum requirements, and the process for consents without a meeting. These updates aim to clarify the governance structure and enhance corporate operations in compliance with legal requirements. The new by-laws address various administrative processes concerning stockholder meetings and voting procedures.
Read more →-RFL
Jun 18, 2025▼ -19.1%on this news
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Phase
Rafael Holdings announced that the Phase 3 TransportNPC study for the treatment of Niemann-Pick Disease Type C1 (NPC1) will continue following a favorable independent review of interim data. The Data Monitoring Committee assessed the investigational drug Trappsol Cyclo's safety and efficacy data and recommended its progression to 96 weeks. Additionally, the FDA has accepted the study's statistical analysis plan, aiding Rafael's development goals. The company recently bolstered its financial position with a $25 million rights offering to support the drug's clinical evaluations.
Read more →-RFL
Jun 11, 2025▼ -27.7%on this news
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Rafael Holdings announced its third quarter fiscal 2025 financial results, reporting a net loss of $4.8 million, down from a previous loss of $32.4 million. The company is optimistic about the upcoming topline data from the interim analysis of the Phase 3 TransportNPC clinical trial for its product Trappsol Cyclo, which aims to treat Niemann-Pick Disease Type C1. Rafael's financial position has been bolstered by the recent completion of a $25 million rights offering. The increase in research and development expenses is attributed to the recent merger with Cyclo Therapeutics.
Read more →-RFL
Jun 4, 2025▲ +12.7%on this news· ran to +58% by day 3
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rafael Holdings, Inc. has announced the successful closing of its $25 million rights offering, resulting in subscriptions for over 3.1 million shares of Class B common stock. CEO Howard Jonas plans to backstop the offering to ensure all shares are subscribed. The proceeds from the offering will support the company's regulatory efforts and potential launch of Trappsol Cyclo, pending positive results from ongoing clinical trials for Niemann-Pick Disease Type C1. The total net proceeds expected from both the rights offering and backstop are approximately $24.9 million.
Read more →-RFL
May 20, 2025Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Deve
Rafael Holdings, Inc. announced an update regarding the subscription rights related to its public warrants. The update is linked to a previously announced $25 million rights offering intended to support the continued development of Trappsol Cyclo. Each subscription right allows shareholders to purchase shares of Class B common stock at a price of $1.28 per share. The rights offering is non-transferable and is set to expire on May 29, 2025, with conditions that may allow for termination prior to expiration. Additionally, the Executive Chairman has committed to purchase any unsold shares in the offering.
Read more →-RFL
May 6, 2025▼ -5.6%on this news
STANDBY PURCHASE AGREEMENT This STANDBY PURCHASE AGREEMENT (this " Agreement ") is made and entered into on
Rafael Holdings, Inc. has entered into a Standby Purchase Agreement with Howard S. Jonas to facilitate a Rights Offering aimed at raising $25 million. Under the agreement, holders of Class A and Class B Common Stock will gain Subscription Rights to purchase additional shares of Class B Common Stock at a price of $1.28 per share. The Standby Purchaser is committed to buying any shares that remain unsubscribed after the offering closes. This arrangement underscores the company's focus on securing necessary funding through shareholder engagement.
Read more →About Rafael Holdings, Inc. Class B Common Stock
Headquarters520 BROAD STREET, NEWARK, NJ, 07120
BIOPHARMAWATCH ELITE PLUS
Trade the next RFL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime